Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
Replimune Group Inc. (Nasdaq: REPL) announces that CEO Philip Astley-Sparke will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:30 a.m. ET. Replimune is a biotechnology company based in Woburn, MA, specializing in developing oncolytic immuno-gene therapies through its Immulytic™ platform. This innovative approach aims to enhance the immune response to tumors and improve cancer treatment efficacy, particularly in conjunction with immune checkpoint blockade therapies.
- None.
- None.
WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat and host investor meetings at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020 at 9:30 a.m. ET.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com.
Replimune Contact
Pamela Esposito, Ph.D.
Replimune Group Inc.
pamela@replimune.com
Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com
FAQ
What is Replimune Group Inc. known for?
When is the BMO Capital Markets 2020 Healthcare Conference?
Who will represent Replimune at the conference?
What is the Immulytic™ platform?
How does Replimune plan to advance its therapies?
